Tag: Kidney Problems: Misc.

Removing race from CKD-EPI will calculate lower eGFR for Black patients and exclude more from receiving chemo

Secondary analysis of randomized trial shows no difference in progression of KDIGO risk scores with daily vitamin D versus placebo

Potential referral volume could be reduced if referral was restricted to patients with predicted risk ≥1 percent in addition to laboratory criteria

Pooled data show roxadustat versus placebo increases hemoglobin levels with an acceptable profile for cardiovascular safety

Variabilities in metabolic syndrome components linked to prognosis, with worse prognosis for more components with high variability

Glucose and lipid components appear to be main drivers for increased risk for all-cause mortality, cardiovascular events

Bilateral deep vein thrombosis, single-session treatment, and female sex tied to greater risk

eGFRcys resulted in smallest change in CKD prevalence among Black adults compared with race-blended, race-removed equations

Third dose of mRNA-1273 vaccine induces serologic response in 49 percent of kidney recipients who did not respond after two doses

Prespecified analysis of RCT shows reduced risk with dapagliflozin versus placebo for composite outcome that included kidney, CV events